ANO8

Across TCGA pan-cancer cohorts, ANO8 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANO8 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ANO8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANO8 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

OV, SARC, and STAD are the cancer types where ANO8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.330	0.843	.002	18	view →
SARC	DFS	Median	All	0.038	0.611	<.001	12	view →
STAD	OS	Median	II,III,IV	0.175	0.660	.005	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	All	0.828	0.384	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANO8–OV (OS)

Open the OV breakdown →